Servier pharmaceutical Co.

Servier is an international pharmaceutical company managed by a non-profit fund, headquartered in Suresnes, France. Servier is widely distributed worldwide, with international operations in 149 countries and a total of 22,000 employees worldwide. As a completely independent company, the group invests an average of 25% of its operating income into drug research and development (excluding generic drugs) every year, and uses all profits for corporate development. The continuous pursuit of innovation in five outstanding areas of cardiovascular disease, immune inflammatory disease, neurodegenerative disease, cancer and diabetes is the driving force for Servier's growth. In addition to drug development, Servier also provides eHealth solutions. ABOUT SERVIER CHINA In 1979, Servier became one of the first multinational companies to enter China. Commitment to care for more than 40 years, Servier China currently covers 29 provinces, cities and regions, and has become the largest professional team of the group; The six regional offices are located in Beijing, Jinan, Shanghai, Hangzhou, Wuhan and Guangzhou. Servier China has maintained its leading position in the industry in the management of cardiovascular diseases and diabetes patients; And will actively expand business in the oncology field. Provide treatment drugs and programs for 3 million patients every day. As Servier’s only industrial production base in Asia, Servier’s Tianjin factory has been committed to Provide our high-quality innovative drugs to patients in China and some Asian countries, and support local clinical research. Focusing on the five major areas of cardiovascular, diabetes, immune inflammation, tumor and neurodegenerative diseases, Servier International Medical Research Center (ICTR) has carried out 52 international and domestic clinical research projects in more than 400 hospitals in Greater China. Nearly 13,000 Chinese patients were enrolled.